LIVMARLI Now Approved in Japan for ALGS and PFIC
Mirum Pharmaceuticals (NASDAQ: MIRM) announced that its partner Takeda Pharmaceutical has received approval from the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® (maralixibat) oral solution. The approval is for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) in Japan.
LIVMARLI becomes the first and only treatment available for these conditions in Japan. Under the exclusive license agreement signed in September 2021, Mirum will receive a percentage of Takeda's annual net sales. The medication is currently approved for ALGS-related pruritus in over 40 countries and for PFIC in more than 30 countries worldwide.
Mirum Pharmaceuticals (NASDAQ: MIRM) ha annunciato che il suo partner Takeda Pharmaceutical ha ricevuto l'approvazione dal Ministero della Salute, del Lavoro e del Welfare giapponese per la soluzione orale LIVMARLI® (maralixibat). L'approvazione riguarda il trattamento del prurito colestatico nei pazienti con sindrome di Alagille (ALGS) e colestasi intraepatica familiare progressiva (PFIC) in Giappone.
LIVMARLI diventa il primo e unico trattamento disponibile per queste condizioni in Giappone. In base all'accordo di licenza esclusiva firmato a settembre 2021, Mirum riceverà una percentuale delle vendite nette annuali di Takeda. Il farmaco è attualmente approvato per il prurito correlato ad ALGS in oltre 40 paesi e per PFIC in più di 30 paesi in tutto il mondo.
Mirum Pharmaceuticals (NASDAQ: MIRM) anunció que su socio Takeda Pharmaceutical ha recibido la aprobación del Ministerio de Salud, Trabajo y Bienestar de Japón para la solución oral LIVMARLI® (maralixibat). La aprobación es para tratar el prurito colestático en pacientes con síndrome de Alagille (ALGS) y colestasis intrahepática familiar progresiva (PFIC) en Japón.
LIVMARLI se convierte en el primer y único tratamiento disponible para estas condiciones en Japón. Según el acuerdo de licencia exclusiva firmado en septiembre de 2021, Mirum recibirá un porcentaje de las ventas netas anuales de Takeda. El medicamento está actualmente aprobado para el prurito relacionado con ALGS en más de 40 países y para PFIC en más de 30 países en todo el mundo.
Mirum Pharmaceuticals (NASDAQ: MIRM)는 파트너 Takeda Pharmaceutical이 일본 보건복지부로부터 LIVMARLI® (maralixibat) 경구 용액에 대한 승인을 받았다고 발표했습니다. 이 승인은 알라질 증후군(ALGS) 및 진행성 가족성 간내 담즙 정체(PFIC) 환자의 담즙 정체성 가려움증 치료를 위한 것입니다.
LIVMARLI는 일본에서 이러한 질환에 대한 첫 번째이자 유일한 치료제가 됩니다. 2021년 9월에 체결된 독점 라이센스 계약에 따라 Mirum은 Takeda의 연간 순매출의 일부를 받게 됩니다. 이 약물은 현재 40개국 이상에서 ALGS 관련 가려움증에 대해, 30개국 이상에서 PFIC에 대해 승인되었습니다.
Mirum Pharmaceuticals (NASDAQ: MIRM) a annoncé que son partenaire Takeda Pharmaceutical a reçu l'approbation du ministère japonais de la Santé, du Travail et du Bien-être pour la solution orale LIVMARLI® (maralixibat). Cette approbation concerne le traitement du prurit cholestatique chez les patients atteints du syndrome d'Alagille (ALGS) et de cholestase intra-hépatique familiale progressive (PFIC) au Japon.
LIVMARLI devient le premier et unique traitement disponible pour ces conditions au Japon. Selon l'accord de licence exclusive signé en septembre 2021, Mirum recevra un pourcentage des ventes nettes annuelles de Takeda. Le médicament est actuellement approuvé pour le prurit lié à l'ALGS dans plus de 40 pays et pour le PFIC dans plus de 30 pays à travers le monde.
Mirum Pharmaceuticals (NASDAQ: MIRM) gab bekannt, dass sein Partner Takeda Pharmaceutical die Genehmigung des japanischen Ministeriums für Gesundheit, Arbeit und Wohlfahrt für die orale Lösung LIVMARLI® (maralixibat) erhalten hat. Die Genehmigung gilt für die Behandlung von cholestatischem Juckreiz bei Patienten mit Alagille-Syndrom (ALGS) und progressiver familiärer intrahepatischer Cholestase (PFIC) in Japan.
LIVMARLI wird die erste und einzige Behandlung für diese Erkrankungen in Japan. Im Rahmen des im September 2021 unterzeichneten exklusiven Lizenzvertrags wird Mirum einen Prozentsatz von Takedas Jahresnettoverkauf erhalten. Das Medikament ist derzeit in über 40 Ländern für mit ALGS verbundenen Juckreiz und in mehr als 30 Ländern weltweit für PFIC zugelassen.
- First-mover advantage as the only approved treatment for ALGS and PFIC in Japan
- Partnership with major pharmaceutical company Takeda for commercialization
- Revenue stream through percentage of annual net sales in Japan
- Expanded global presence with approvals in 40+ countries for ALGS and 30+ for PFIC
- Revenue dependent on Takeda's sales performance and execution
- LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in
“We are thrilled to see LIVMARLI approved as the first and only medication available in
Mirum and Takeda entered into an exclusive license agreement in September 2021 for the development and commercialization of LIVMARLI for rare cholestatic pediatric liver diseases in
LIVMARLI is currently approved for the treatment of pruritus related to ALGS in more than 40 countries and for PFIC in more than 30 countries worldwide.
About LIVMARLI® (maralixibat) oral solution
LIVMARLI® (maralixibat) oral solution is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved by the
LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.
Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump (BSEP) protein.
LIVMARLI can cause side effects, including:
Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or may lead to liver transplant or death. Your healthcare provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen), bloating in your stomach area, loss of appetite or bleeding or bruising more easily than normal.
Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain. Your healthcare provider may advise you to monitor for new or worsening stomach problems including stomach pain, diarrhea, blood in your stool or vomiting. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.
A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat is common in patients with Alagille syndrome and PFIC but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment and may monitor for bone fractures and bleeding which have been reported as common side effects.
US Prescribing Information
EU SmPC
Canadian Product Monograph
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the impact of LIVMARLI on patients in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327866446/en/
Media Contact:
Erin Murphy
media@mirumpharma.com
Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.